The IPO of Rubicon Research Ltd opened for bidding from October 9 to October 13, 2025. The ₹1,377.50 crore mainboard issue included a fresh issue of ₹500 crore and an offer-for-sale of ₹877.5 crore by General Atlantic Singapore RR Pte Ltd. The price band of ₹461 to ₹485 per equity share, and the market lot was 30 shares (minimum investment of ₹14,550 on the higher band). The stocks have been listed on both BSE and NSE platforms. Investors from all categories expressed tremendous interest, leading to a subscription level of 103.90× in aggregate, with qualified institutional bids going as high as 130.26×, and those from retail investors at 35.02×.

Company Performance and Fundamentals

Specialty and generic pharmaceuticals company Rubicon Research has been recording steady financial growth i

See Full Page